Drug Trial News

RSS

Angiotensin receptor blockers do not increase risk of cancer: FDA

The U.S. Food and Drug Administration today announced that a group of medications used to control high blood pressure, called angiotensin receptor blockers (ARBs), do not increase the risk of developing cancer in patients using the medications.

3 Jun 2011

Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

iBio, Inc. today announced positive interim results from a Phase 1 clinical trial of an iBioLaunch platform-produced subunit vaccine directed against Influenza A/California/04/09 (H1N1).

3 Jun 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

3 Jun 2011

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of STX209 on social impairment in adolescents and adults with fragile X syndrome.

2 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

Positive interim results from Fraunhofer USA CMB's HAC1 influenza vaccine Phase 1 trial

Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen announced today that Phase 2 data will be presented from an open-label, multi-center clinical trial evaluating the safety and tolerability of rozrolimupab in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP) at the 16th Congress of the European Hematology Association meeting in London, UK on June 10 from 5:45 to 7:00 PM.

2 Jun 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C

Anadys Pharmaceuticals, Inc. today announced issuance of the U.S. patent covering setrobuvir, the Company's Direct-Acting Antiviral in Phase IIb development for chronic hepatitis C virus infection.

2 Jun 2011

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Somnus Therapeutics, Inc., a private specialty pharmaceutical company, has completed a Phase 2 dose-ranging study of SKP-1041, a modified-release formulation of zaleplon.

2 Jun 2011

Fero Industries completes Sucanon human clinical trials on Type-2 diabetes

Fero Industries, Inc. is pleased to announce that independent human clinical trials of Sucanon have been successfully completed in the Middle East.

2 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.

1 Jun 2011

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Symphogen announced today that the company will present preliminary Phase 1 data evaluating the company's lead cancer compound, Sym004, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago.

1 Jun 2011

Diamyd European Phase III study in diabetes does not meet primary endpoint

Diamyd Medical AB reports that the Company has decided not to complete the follow-up period of a European Phase III study with the antigen-based therapy Diamyd.

1 Jun 2011

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

CrystalGenomics, Inc. and CG Pharmaceuticals, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis.

1 Jun 2011

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

After years of building hope for a treatment, Rochester researchers and clinicians will begin the first controlled clinical trial for Juvenile Batten disease this summer, thanks to $1 million in grants from the Food and Drug Administration and the Batten Disease Support and Research Association.

1 Jun 2011

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion.

1 Jun 2011

Drug Trial News

Angiotensin receptor blockers do not increase risk of cancer: FDA

Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Positive interim results from Fraunhofer USA CMB's HAC1 influenza vaccine Phase 1 trial

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Fero Industries completes Sucanon human clinical trials on Type-2 diabetes

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Diamyd European Phase III study in diabetes does not meet primary endpoint

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News